Clarus Therapeutics Holdings, Inc. – NASDAQ:CRXT

Add to watchlist

$0.048

+0.00

+20.3%

Market closed

Open in about 7 hours

-15.79%

month

-89.47%

quarter

Market Cap	N/A
Enterprise value	21.76M

P/E	-0.01
EV/Sales	1.13
EV/EBITDA	-0.65
Price/Sales	0.02
Price/Book	-0.03
PEG ratio	N/A
EPS	-6.39

Revenue	19.23M
EBITDA	-33.02M
Income	-58.62M
Revenue Q/Q	45.73%
Revenue Y/Y	284.54%

Profit margin	-249.84%
Oper. margin	-207.41%
Gross margin	79.26%
EBIT margin	-207.41%
EBITDA margin	-171.65%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT): Profit margin
Sep 2021	4.28M	-2.76M	-64.61%
Dec 2021	6.89M	-26.30M	-381.66%
Mar 2022	4.01M	-16.83M	-419.72%
Jun 2022	4.05M	-12.71M	-313.93%

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT): Earnings per share (EPS)
2022-03-30	-0.68	-0.19
2022-05-16	-0.4	-0.61
2022-08-18	-0.29	-0.24

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT): Payout ratio
Payout ratio	0%

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT): Dividend Yield
2020
2021	13.25%

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT): Debt to assets
Sep 2021	45322000	70.84M	156.32%
Dec 2021	51708000	67.62M	130.79%
Mar 2022	36522000	66.87M	183.12%
Jun 2022	48940000	62.00M	126.69%

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT): Cash Flow
Sep 2021	-34.26M	-20K	49.19M
Dec 2021	-9.33M	-5K	13.80M
Mar 2022	-17.26M	-10K	-3.78M
Jun 2022	-17.50M	0	2.02M

Clarus Therapeutics Holdings alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Clarus Therapeutics Holdings
Employees

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT): Employee count
Aug 2023	16
Sep 2023	16
Oct 2023	16
Nov 2023	16
Dec 2023	16
Jan 2024	16
Feb 2024	16
Mar 2024	16
Apr 2024	16
May 2024	16
Jun 2024	16
Jul 2024	16

Clarus Therapeutics Holdings
Insider Trading

Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT): Insider trades (number of shares)
Period	Buy	Sel
Sep 2021	0	127360

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	17 Sep 2021	FFI FUND LTD 10 percent owner 10 percent owner	Common Stock	127,360	$9.2	$1,171,712
Option	9 Sep 2021	HERNANDEZ JOSEPH director director	Class B Common Stock	1,437,500	N/A	N/A
Option	9 Sep 2021	HERNANDEZ JOSEPH director director	Common Stock	1,437,500	N/A	N/A

CRXT insider trading transactions

Clarus Therapeutics Holdings
Earnings Call Transcripts

Quarter	Transcript
Q1 2022 16 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 30 Mar 2022	Q4 2021 Earnings Call Transcript
Q3 2021 18 Nov 2021	Q3 2021 Earnings Call Transcript

CRXT earnings call transcripts

Clarus Therapeutics Holdings
Latest News

Tuesday, 6 September 2022
18:41	Clarus Therapeutics (CRXT) Stock: Why It Fell 31.16%	Pulse2
Friday, 2 September 2022
20:22	These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)	24/7 Wall Street
Monday, 29 August 2022
08:45	Clarus Therapeutics (CRXT) Stock Plunges Ahead of Aug. 31 Delisting	InvestorPlace
Thursday, 25 August 2022
11:51	Top Penny Stocks To Buy? 4 For Your Watch List Before Next Week	PennyStocks
Saturday, 30 July 2022
11:30	Top Tricks for Trading Penny Stocks Right Now, 3 Tips	PennyStocks
Tuesday, 5 July 2022
17:13	Hot Penny Stocks to Buy This Week? 3 to Watch Right Now	PennyStocks
Wednesday, 22 June 2022
19:52	Hot Penny Stocks to Buy in July? Check These 3 Out	PennyStocks
Monday, 16 May 2022
19:19	Clarus Therapeutics Holdings, Inc. (CRXT) CEO Bob Dudley on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Wednesday, 4 May 2022
15:17	Hot Penny Stocks You Need to Know About This Month	PennyStocks
Tuesday, 3 May 2022
14:48	Hot Penny Stocks To Buy For Under $1 This Week	PennyStocks
Tuesday, 26 April 2022
14:57	Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?	PennyStocks
Monday, 25 April 2022
12:00	Why Clarus Therapeutics Shares Are Getting Hammered	Benzinga
Sunday, 24 April 2022
16:30	3 Hot Penny Stocks to Add to Your Small-Caps Watch List This Week	PennyStocks
Tuesday, 19 April 2022
09:05	Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting	GlobeNewsWire
Thursday, 14 April 2022
09:30	Best Penny Stocks to Buy? 3 to Watch as Musk Offers $43B for TWTR	PennyStocks
Wednesday, 30 March 2022
21:17	Clarus Therapeutics Holdings' (CRXT) CEO Bob Dudley on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Tuesday, 29 March 2022
16:05	Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results	GlobeNewsWire
Monday, 28 March 2022
17:05	3 Hot Meme Penny Stocks to Watch Under $3 Right Now	PennyStocks
Friday, 25 March 2022
13:57	Best Reddit Penny Stocks to Watch During Trading Today	PennyStocks
Monday, 21 March 2022
16:37	4 Trending Penny Stocks to Add to Your Watchlist Right Now	PennyStocks

Frequently Asked Questions (FAQ)

What's the price of Clarus Therapeutics Holdings stock today?

One share of Clarus Therapeutics Holdings stock can currently be purchased for approximately $0.05.
When is Clarus Therapeutics Holdings's next earnings date?

Unfortunately, Clarus Therapeutics Holdings's (CRXT) next earnings date is currently unknown.
Does Clarus Therapeutics Holdings pay dividends?

No, Clarus Therapeutics Holdings does not pay dividends.
What is Clarus Therapeutics Holdings's stock symbol?

Clarus Therapeutics Holdings, Inc. is traded on the NASDAQ under the ticker symbol "CRXT".
What is Clarus Therapeutics Holdings's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - General industry.
How do i buy shares of Clarus Therapeutics Holdings?

Shares of Clarus Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Clarus Therapeutics Holdings have?

As Jul 2024, Clarus Therapeutics Holdings employs 16 workers.
When Clarus Therapeutics Holdings went public?

Clarus Therapeutics Holdings, Inc. is publicly traded company for more then 4 years since IPO on 7 Sep 2021.
What is Clarus Therapeutics Holdings's official website?

The official website for Clarus Therapeutics Holdings is clarustherapeutics.com.
Where are Clarus Therapeutics Holdings's headquarters?

Clarus Therapeutics Holdings is headquartered at 555 Skokie Boulevard, Northbrook, IL.
How can i contact Clarus Therapeutics Holdings?

Clarus Therapeutics Holdings's mailing address is 555 Skokie Boulevard, Northbrook, IL and company can be reached via phone at +84 75624300.

Clarus Therapeutics Holdings, Inc.

clarustherapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Drug Manufacturers - General

Sector:

Healthcare

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

+84 75624300

555 Skokie Boulevard
Northbrook, IL 60062

CIK: 0001817944
ISIN: US18271L1070
CUSIP: 18271L107